HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
Asia Biotech Live
LATEST UPDATES » Vol 24, No 01, January 2020 – Empowering the Patient - Personalization of Diabetes Management       » First of its kind Human Heart-in-a-Jar Model for therapeutic solutions       » China's National Vaccine Tracking System set to be completed in 2020       » China's amended drug administration law kicks in       » Human activity puts Chinese plant biodiversity at risk, study finds       » Contributory effects of each brain cell type in development of Alzheimer's Disease      
EYE ON CHINA
Wuhan Healthgen Biotechnology gains approval for OsrHSA by U.S. FDA
A Wuhan-based biotechnology company in central China's Hubei province received approval by the US Food and Drug Administration for clinical trials of its OsrHSA, a recombinant human serum albumin derived from rice grains.

The clinical trials test potential treatments in human volunteers to see whether they should be approved for wider use in the general population. Approval was announced on 10 August 2019.

It is the first time for a Chinese product of this kind to get the approval, paving the way for the company to enter the US market, according to a report from Hubei Daily.

The human serum albumin is the most abundant protein in human plasma. It can transport hormones, lipids and other molecules while maintaining osmotic pressure, according to the company's official website.

Statistics show in the next few years, the global market demand for human serum albumin is expected to reach 3,800 tons per year, and China's annual demand is forecast to be 700 tons.

Currently, human serum albumin can only be derived from plasma. In 2018, the consumption of serum albumin in China was 468 tons.

According to Healthgen Biotechnology Corp, OsrHSA provides an excellent solution for an animal-free medium, has higher purity and excellent batch consistency, compared with FBS, pHSA and BSA.

OsrHSA is widely used as excipient, stabilizer and embedding agent in bio-pharmaceutical applications, per the company's website.

Yang Daichang, chairman of the company, was quoted by Hubei Daily saying after more than a decade of research and development, the technology has large-scale application value and is expected to replace plasma extraction.

In 2017, OsrHSA entered the human clinical trial stage in China. Previously, researchers completed experiments in rats, monkeys, rabbits and other animals. The results show human serum albumin extracted from rice has no significant difference from human plasma extraction, and by some measures is even better.

Source: China Daily

Click here for the complete issue.

NEWS CRUNCH  
news Joining Forces to Elevate Asia's Healthcare Industry
news 4th Global Feed Summit draws Feed Producers, Technology Providers, Raw Materials Suppliers to Bangkok for Key Discussions
news 2nd China Pharma Digital Innovation Summit to be held in Shanghai
news 2nd China Healthcare Digital Innovation Summit to be held in Shanghai
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy